Cemiplimab Treatment in Patients With Locally Advanced and Metastatic Secondary Angiosarcomas
Latest Information Update: 12 Jul 2024
At a glance
- Drugs Cemiplimab (Primary)
- Indications Haemangiosarcoma
- Focus Therapeutic Use
- Acronyms CEMangio
- 04 Jun 2024 Results (At the cutoff date 23-Jan-24) assessing safety and efficacy of Cemiplimab in locally advanced and/or metastatic secondary angiosarcomas presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 19 Jan 2022 Planned primary completion date changed from 1 May 2024 to 1 Jul 2024.
- 26 Nov 2021 Status changed from not yet recruiting to recruiting.